Can engineered strategies in biology be employed to modify and remodel viruses?

In the ongoing battle against infectious diseases, a new ally is emerging in the form of synthetic biology. This interdisciplinary field, which combines engineering principles with biology, is reshaping the landscape of vaccine development.

At the heart of this revolution are Virus-like Particles (VLPs), self-assembled viral proteins that mimic the structural features of viruses without carrying their genetic content. These particles, devoid of genomic material, are highly promising as safe and effective vaccine candidates.

Nucleic acid vaccines, another innovation in the field, offer rapid design and production processes. This speed allows for the targeting of virtually any protein epitope, a significant advantage in the fight against rapidly evolving infectious diseases.

Key players in this synthetic biology-based vaccine race include academic-founded biotech startups, research centres like the Molecular Targets and Therapeutics Centre at Helmholtz Munich, and innovative biotech companies in Austria. Clinical research teams at institutions like MDC Berlin are also conducting studies to improve vaccine responses.

One innovative approach in antigen development is genomic codon deoptimization, a method that redesigns viral genomes using large-scale silent mutations to reduce viral protein production in human cells. This technique is crucial for providing a successful response to rapidly evolving infectious diseases.

Material science and lipid nanoparticles (NPs) are used to condense, protect, and enhance the delivery of RNA into cells, addressing their stability issues. Synthetic biology also offers new methods for purifying and formulating biopharmaceuticals, potentially enhancing their stability and shelf life.

Modern DNA vaccines have improved immunogenicity through various means, including codon optimization, the simultaneous application of immune-stimulating cytokines, streamlined plasmid designs, plasmid-free double-stranded DNA (dsDNA) constructs, and needle-free, electroporation-free intramuscular injections.

RNA vaccines, while promising, face challenges due to their lower stability compared to DNA and rapid degradation. However, they do not require electroporation to pass through the lipid bilayer.

VLP-based vaccines are already available for certain diseases like HPV and Hepatitis B, with ongoing research for many others. Existing methods allow for the design and production of effective vaccines within weeks after obtaining the genetic information of a new pathogen, enabling a quicker response to pandemics.

Optimizing cell lines genetically can increase production efficiency and reduce production costs in vaccine production processes. Viral vectors like adenoviruses and lentiviruses, while widely used due to their high efficiency and broad target cell range, have safety and immunogenicity issues associated with their clinical use.

Synthetic biology and virology complement each other in development processes, contributing to the production of safer and more effective approaches. Multi-antigen vaccines and designs capable of eliciting combined immune responses could provide broader and longer-lasting protection.

Product development typically consists of several main stages: Antigen Identification and Design, Research and Development, Preclinical Trials, Clinical Trials, and Production and Distribution. As synthetic biology continues to evolve, it could enable greater customization and specialization in vaccine production, including the development of personalized cancer therapies.

In conclusion, synthetic biology is revolutionizing the vaccine development landscape, offering rapid, safe, and effective solutions to combat infectious diseases. Its potential extends beyond vaccines, promising a future where personalized medicine becomes a reality.